CVS Jun 2020 42.500 put

OPR - OPR Delayed Price. Currency in USD
0.6300
0.0000 (0.00%)
As of 9:30AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.6300
Open0.6300
Bid0.0000
Ask0.0000
Strike42.50
Expire Date2020-06-19
Day's Range0.5200 - 0.5200
Contract RangeN/A
Volume2
Open InterestN/A
  • Walmart opens its first-ever medical center and one analyst thinks it's really cool
    Yahoo Finance

    Walmart opens its first-ever medical center and one analyst thinks it's really cool

    Walmart could be signaling its foray into more health services.

  • GlobeNewswire

    SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS CVS, GVA, IFF, PS INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

    NEW ORLEANS, Sept. 16, 2019 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending.

  • ACCESSWIRE

    SHAREHOLDER ALERT: VNTR CURLF CVS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, NY / ACCESSWIRE / September 16, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered ...

  • ACCESSWIRE

    IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against CVS Health Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / September 16, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CVS Health Corporation (“CVS” ...

  • Deutsche Bank: Catch These 3 Healthcare Stocks Ahead of U.S. Elections
    TipRanks

    Deutsche Bank: Catch These 3 Healthcare Stocks Ahead of U.S. Elections

    Ahead of the U.S. 2020 presidential election, some investors are concerned that discussions regarding healthcare reform could take a toll on both share prices and valuations. That being said, one analyst believes that compelling investment opportunities can still be found within the managed care space. Managed care refers to various healthcare plans that try to reduce costs by controlling the type and level of services provided.Deutsche Bank’s George Hill just initiated coverage on 3 healthcare stocks, giving each a Buy rating based on their “attractive” potential for growth on September 11. Using the TipRanks Stock Comparison tool, we compared how the stocks measure up against each other based on year-to-date gain, analyst consensus as well as average analyst price target. Each of these stocks has amassed significant support from other Wall Street analysts with a “Strong Buy” analyst consensus. This is based on the last three months’ worth of ratings from the rest of the Street. Let’s dive in. CVS Health CVS Health (CVS\- Get Report) provides health plans and services under three segments that include pharmacy services, retail and long-term care as well as health care benefits. Out of the three healthcare stocks on our list, Hill cites CVS as his top pick based on its level of diversification. While shares are down 2% year-to-date, CVS has slowly but surely been working its way back up gaining 18% in the last three months. With all that the drug store and pharmacy chain has going for it, Hill sees even more growth on the way. It has about 10,000 pharmacies across the U.S. and plans to open 1,500 HealthHub stores by the end of 2021. He also highlights its integrated care delivery, which can improve beneficiary care as well as cut costs.That being said, a significant portion of its revenue is generated from its non-managed care organization (MCO) segments. CVS’ non-MCO businesses include the largest PBM, the second-largest pharmacy chain, long-term care and other services. While some investors originally expressed concerns regarding its $70 billion acquisition of health insurer Aetna in 2018, management has tried to mitigate any fears. On June 4, the company conveyed that once the two companies are fully integrated, it could see low-double digit percent earnings growth by 2022. Hill argues that the company is poised to meet its guidance based on its business strategy. “We see the company as well positioned to deliver on a vertical integration care delivery strategy, allowing the company to take share and generate positive earnings surprise. We also see the valuation of CVS shares as highly compelling and capturing potential execution and integration risks,” he explained. As a result, the three-star analyst initiated coverage with a Buy and set a $91 price target, suggesting 42% upside. All in all, the rest of the Street takes a similar position. CVS boasts a ‘Strong Buy’ analyst consensus and a $72 average price target, indicating 13% upside potential, the lowest on the list. Anthem Inc. While shares of the health insurer have slid 3% year-to-date, Hill tells investors that the dip in Anthem (ANTM\- Get Report) presents a unique buying opportunity. Recently, Anthem has attracted attention for its new PBM strategy. The company announced in March that its PBM, IngenioRX, will be more transparent and customer-friendly, with the new PBM passing along rebates to pharmacy customers. Traditional PBMs get rebate payments from drug manufacturers in exchange for placing medications on PBMs’ lists of covered drugs, or formularies. According to management, this new strategy could reduce costs and simplify services.It should be noted that IngenioRx is the product of its partnership with CVS that involves a five-year agreement signed back in 2017. CVS has its own Caremark PBM, and only processes claims and handles tasks related to prescription fulfillment for IngenioRX. Anthem has full control over clinical strategy and decides which drugs are covered. In addition to revamping its PBM strategy, its 2018 acquisitions of Aspire Health and America’s 1st Choice as well as HealthSun in 2017 are expected to drive substantial Medicare Advantage growth. Medicare Advantage plans are an alternative to original medicare that let beneficiaries choose to get their coverage through private insurance companies that contract with Medicare.While all of the above supports a strong long-term growth narrative, Hill notes that there are some risks associated with Anthem. “While execution has been strong recently, we see some implementation risk on the company’s PBM strategy, risk to the company’s Medicare Advantage growth targets, less exposure to faster-growing segments of the market and a rich relative valuation,” he stated. Nonetheless, the potential reward outweighs this risk. With his coverage initiation, Hill set a $323 price target which implies 28% upside. With 7 Buy ratings vs no Holds or Sells received in the last three months, the word on the Street is that ANTM is a ‘Strong Buy’. Its $345 average price target demonstrates the potential for 36% upside, the highest on our list. Cigna CorporationAs Cigna (CI\- Get Report) shares have declined 15% year-to-date, the Deutsche Bank analyst argues that shares are now trading at a discount. Some investors have expressed concerns that the health insurance company is overexposed in both the PBM and commercial business space. In December 2018, CI finalized its $67 billion merger with PBM Express Scripts in order to expand its reach within the sector. The merger could be a problem for CI as regulations have been proposed that would impair the PBM business model. This poses a major threat to CI as its primary non-MCO revenue comes from large PBMs. While no legislation has been passed yet, there is always a possibility that this could change. A significant portion of CI’s revenue is also generated from its commercial products. The commercial MCO space includes risk-bearing insurance and administrative services only (ASO). Hill states that while this space can be more profitable, it is slower growing than the government-pay business as the commercial business is largely stagnant. While acknowledging that Cigna is behind the curve in terms of its reach within the government-pay space, he still believes the stock is poised to soar. “We view Cigna’s PBM segment earnings as not having significant short-term earnings risk and the company’s diversified earnings stream as undeserving of the steep discount applied to the shares in the wake of the Express Scripts merger,” he explained. As a result, the analyst initiated coverage with a Buy and set a $207 price target. The price target reflects his confidence in CI’s ability to surge 29% over the next twelve months.Wall Street seems to agree with Hill. CI has only been assigned Buy ratings in the last three months. Its average price target of $214 indicates 33% upside potential, falling just short of ANTM’s.    Find Wall Street’s most loved stocks with the Top Analysts’ Stocks tool

  • ACCESSWIRE

    CVS Health Corporation (CVS), NetApp, Inc. (NTAP) & SAExploration Holdings, Inc. (SAEX) - Upcoming Class Actions - Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, NY / ACCESSWIRE / September 16, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.

  • Barrons.com

    First Walmart Health Clinic ‘Stole the Show,’ Analyst Says After Tour

    Jefferies analyst Christopher Mandeville took a sneak-peek of Walmart’s first stand-alone health clinic and came back raving about the initiative.

  • 5 Stocks in the Limelight After Recent Broker Rating Upgrade
    Zacks

    5 Stocks in the Limelight After Recent Broker Rating Upgrade

    Broker opinion acts as a valuable guide for investors while deciding their course of action on a particular stock.

  • Top Ranked Momentum Stocks to Buy for September 16th
    Zacks

    Top Ranked Momentum Stocks to Buy for September 16th

    Top Ranked Momentum Stocks to Buy for September 16th

  • GlobeNewswire

    CLASS ACTION UPDATE for CARB, TWOU, CVS and MDP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, Sept. 16, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..

  • Business Wire

    IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against CVS Health Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CVS Health Corporation (“CVS” or “the Company”) (NYSE: CVS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who acquired shares of CVS in exchange for their shares of Aetna Inc. in connection with CVS’s acquisition of Aetna on November 28, 2018, are encouraged to contact the firm before October 14, 2019. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge.

  • ACCESSWIRE

    The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of VNTR, CURLF and CVS

    NEW YORK, NY / ACCESSWIRE / September 16, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...

  • ACCESSWIRE

    CVS NOTICE, ROSEN, A TOP RANKED LAW FIRM, Announces Securities Class Action Lawsuit Against CVS Health Corporation Seeking Recovery of Investor Losses - CVS

    NEW YORK, N.Y. / ACCESSWIRE / September 15, 2019 / Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of all former Aetna Inc. shareholders who ...

  • ACCESSWIRE

    CLASS ACTION UPDATE for JE, CVS and MDP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, NY / ACCESSWIRE / September 15, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below.

  • Business Wire

    IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against CVS Health Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CVS Health Corporation (“CVS” or “the Company”) (NYSE: CVS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who acquired shares of CVS in exchange for their shares of Aetna Inc. in connection with CVS’s acquisition of Aetna on November 28, 2018, are encouraged to contact the firm before October 14, 2019. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge.

  • GlobeNewswire

    SHAREHOLDER ALERT: CLAIMSFILER REMINDS CVS, GVA, IFF, PS INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

    NEW ORLEANS, Sept. 13, 2019 -- ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:.

  • GuruFocus.com

    Cvs Health Corp (CVS) EVP & CFO Eva C Boratto Sold $528,450 of Shares

    EVP & CFO of Cvs Health Corp (30-Year Financial, Insider Trades) Eva C Boratto (insider trades) sold 8,130 shares of CVS on 09/12/2019 at an average price of $65 a share. Continue reading...

  • ACCESSWIRE

    The Gross Law Firm Announces Class Actions on Behalf of Shareholders of OMCL, CURLF and CVS

    NEW YORK, NY / ACCESSWIRE / September 13, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.

  • Business Wire

    EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against CVS Health Corporation – CVS

    Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of all former Aetna Inc. shareholders who acquired CVS Health Corporation (CVS) shares in exchange for their Aetna shares in connection with CVS’s acquisition of Aetna on November 28, 2018. The lawsuit seeks to recover damages for CVS investors under the federal securities laws. To join the CVS class action, go to https://www.rosenlegal.com/cases-register-1674.html or call Phillip Kim, Esq.

  • ACCESSWIRE

    SHAREHOLDER ALERT: NGHC TWOU CVS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, NY / ACCESSWIRE / September 13, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered ...

  • GlobeNewswire

    CVS Health Corporation (CVS), NetApp, Inc. (NTAP) & SAExploration Holdings, Inc. (SAEX) - Class Action Alert - Bronstein, Gewirtz & Grossman, LLC

    Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

  • SmileDirectClub must quickly show investors profits: strategists
    Yahoo Finance

    SmileDirectClub must quickly show investors profits: strategists

    SmileDirectClub needs to show profits quickly in the wake of its tough first day of trading, says two strategists.

  • ACCESSWIRE

    The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NGHC, JE and CVS

    NEW YORK, NY / ACCESSWIRE / September 13, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

  • Here's What We Know About How Drugs Are Priced — And What We Don't
    Investor's Business Daily

    Here's What We Know About How Drugs Are Priced — And What We Don't

    Pharmaceutical companies and middlemen known as pharmacy benefit managers are generally at odds in a battle over drug prices. So, who is actually responsible for high prescription prices?

  • ACCESSWIRE

    CVS Health Corporation (CVS), NetApp, Inc. (NTAP) & SAExploration Holdings, Inc. (SAEX) - Class Action - Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, NY / ACCESSWIRE / September 13, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.